source
- Biogen reports mixed results in mid‑stage trial of tau‑targeting Alzheimer’s therapyBiogen disclosed data from a Phase 2 study of its experimental Alzheimer’s drug that targets the tau protein. The trial showed a combination of positive and negative signals, with some measures ind…
- CREATE Medicines raises $122 million to advance CAR-T candidates into human trialsCREATE Medicines, formerly Myeloid Therapeutics, announced a $122 million financing round. The funding came from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners and other invest…